Please provide your email address to receive an email when new articles are posted on . The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ...

In this figure you can see all of the diseases that were identified linked to epithelial barrier defect and microbial dysbiosis linked to epithelial barrier damaging environmental substances In this ...

(RTTNews) - KALA BIO Inc. (KALA) is in focus, as anticipation builds around its upcoming clinical trial data for KPI-012, a novel stem cell-derived therapy targeting persistent corneal epithelial ...

KALA BIO completes patient enrollment in CHASE trial, evaluating KPI-012 for treating persistent corneal epithelial defect, with results due Q3 2025. KALA BIO, Inc. announced the completion of patient ...

The repair of corneal injuries remains a major challenge in clinical practice. Impaired corneal wound healing is closely associated with aberrantly activated stromal keratocytes and disorganized ...

Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...

Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...

Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patient has been dosed in the US in a Phase 3 study of cenegermin-bkbj ophthalmic solution for the ...

Marc Chanson Full Professor Department of Cell Physiology and Metabolism UNIGE Faculty of Medicine Marc.Chanson@unige.ch Apicobasal polarity plays key roles in airway epithelial maturation and ...